Role of Medical Management for Uterine Leiomyomas.

Banafsheh N Kashani, Gabriele Centini, Sara S Morelli, Gerson Weiss, Felice Petraglia

Journal: Best practice & research. Clinical obstetrics & gynaecology 2017;34():85-103

PMID: 26796059

Full Text on Elsevier Science View on PubMed

Abstract

Uterine leiomyomas, or fibroids, are the most common benign tumor in reproductive aged women. Affected women may remain asymptomatic or may report symptoms related to abnormal uterine bleeding, infertility, or pelvic pain and pressure. Depending on a patient's symptomatology and reproductive plans, treatment options include expectant management, medical management (hormonal and non-hormonal), or surgical management (myomectomy or hysterectomy). In those wishing to defer surgical management, non-hormonal therapies such as non-steroidal anti-inflammatory drugs and tranexamic acid have been shown to decrease menstrual blood loss. In patients with more symptomatic leiomyomas, hormonal therapies such as gonadotropin-releasing hormone agonists and selective progesterone receptor modulators are effective at reducing leiomyoma volume, uterine size, and menstrual blood loss. This manuscript will detail the available and emerging hormonal and non-hormonal treatments for symptomatic uterine leiomyomas.

Address: Department of Obstetrics, Gynecology and Women's Health, Rutgers, New Jersey Medical School, Newark, NJ, USA. Electronic address: [email protected].; Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.; Department of Obstetrics, Gynecology and Women's Health, Rutgers, New Jersey Medical School, Newark, NJ, USA.

DOI: 10.1016/j.bpobgyn.2015.11.016

Link outs

Free resources

Medical:

Other Literature Sources:

https://scite.ai/reports/26796059

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-PGR-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Antifibrinolytic Agents, Aromatase Inhibitors, Cabergoline, Cholecalciferol, Contraceptive Agents, Female, Contraceptives, Oral, Hormonal, Contraceptives, Oral, Synthetic, Danazol, Dopamine Agonists, Ergolines, Estrenes, Estrogen Antagonists, Female, Gestrinone, Gonadotropin-Releasing Hormone, Humans, Intrauterine Devices, Medicated, Leiomyoma, Levonorgestrel, Mifepristone, Norpregnadienes, Oximes, Patient Care Planning, Selective Estrogen Receptor Modulators, Somatostatin, Tranexamic Acid, Uterine Neoplasms, Vitamins